{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:34:48Z","timestamp":1792164888807,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Verin f\u00fcr Neurowissenschaftliche Tagungen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00702-017-1705-z","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T10:36:15Z","timestamp":1489574175000},"page":"745-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"124","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Gr\u00fcnblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","volume":"355","author":"AO Bar","year":"2004","unstructured":"Bar AO, Amit T, Youdim MB (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169\u2013172","journal-title":"Neurosci Lett"},{"key":"1705_CR2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00702-013-1120-z","volume":"121","author":"J Bartl","year":"2014","unstructured":"Bartl J, M\u00fcller T, Gr\u00fcnblatt E, Gerlach M, Riederer P (2014) Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 121:379\u2013383","journal-title":"J Neural Transm"},{"key":"1705_CR3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/j.1552-4604.1997.tb04342.x","volume":"37","author":"EH Heinonen","year":"1997","unstructured":"Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykko KA, Lammintausta RA (1997) Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 37:602\u2013609","journal-title":"J Clin Pharmacol"},{"key":"1705_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4137\/CMT.S1169","volume":"2","author":"T M\u00fcller","year":"2010","unstructured":"M\u00fcller T (2010) The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson\u2019s disease. Clin Med Insights Therap 2:155\u2013168","journal-title":"Clin Med Insights Therap"},{"key":"1705_CR5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, Foley P (2017) Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet 56:251\u2013261","journal-title":"Clin Pharmacokinet"},{"key":"1705_CR6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","volume":"120","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson\u2019s disease. J Neural Transm 120:761\u2013765","journal-title":"J Neural Transm"},{"key":"1705_CR7","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1016\/j.bmc.2013.08.019","volume":"21","author":"S Nag","year":"2013","unstructured":"Nag S, Lehmann L, Kettschau G, Toth M, Heinrich T, Thiele A, Varrone A, Halldin C (2013) Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). Bioorg Med Chem 21:6634\u20136641","journal-title":"Bioorg Med Chem"},{"key":"1705_CR8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0161-813X(03)00099-8","volume":"25","author":"M Naoi","year":"2004","unstructured":"Naoi M, Maruyama W, Nagy GM (2004) Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. Neurotoxicology 25:193\u2013204","journal-title":"Neurotoxicology"},{"key":"1705_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","volume":"20","author":"P Riederer","year":"2011","unstructured":"Riederer P, Laux G (2011) MAO-inhibitors in Parkinson\u2019s Disease. Exp Neurobiol 20:1\u201317","journal-title":"Exp Neurobiol"},{"key":"1705_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/17425255.2017.1273901","volume":"13","author":"P Riederer","year":"2017","unstructured":"Riederer P, M\u00fcller T (2017) Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol 13:233\u2013240","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1705_CR11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00702-002-0778-4","volume":"110","author":"SA Treseder","year":"2003","unstructured":"Treseder SA, Rose S, Summo L, Jenner P (2003) Commonly used l-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat. J Neural Transm (Vienna) 110:229\u2013238","journal-title":"J Neural Transm (Vienna)"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-017-1705-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1705-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1705-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T08:27:54Z","timestamp":1495873674000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-017-1705-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s00702-017-1705-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}